Drug Profile
RM 02
Alternative Names: RM-02Latest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator CutisPharma
- Developer Azurity Pharmaceuticals; Dr Reddys Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Gastrointestinal disorders
Most Recent Events
- 06 Apr 2022 RM 02 is still in Pre-registration for Gastrointestinal disorders in US (Azurity Pharmaceuticals pipeline, April 2022)
- 06 Apr 2022 Preregistration for Gastrointestinal disorders in USA (unspecified route) (Azurity Pharmaceuticals pipeline, April 2022)
- 12 Jun 2019 CutisPharma is now called Azurity Pharmaceuticals